Diagnostic performance of PET/CT with tracers other than F-18-FDG in oncology: An evidence-based review

Clinical and Translational Oncology

Volumn 16, Issue 9, 2014, Pages 770-775

  Treglia, G ^a   Sadeghi, R ^b   Del Sole, A ^c,d   Giovanella, L ^a  

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SAN PAOLO HOSPITAL   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Evidence; Meta analysis; Oncology; PET; PET CT; Tracer

Indexed keywords

6 FLUORODOPA F 18; ACETIC ACID C 11; CHOLINE C 11; DOTANOC GA 68; DOTATATE GA 68; DOTATOC GA 68; FLUORINE 18; FLUORO ETHYL TYROSINE F 18; FLUORODEOXYGLUCOSE F 18; METHIONINE C 11; TRACER; UNCLASSIFIED DRUG; RADIOPHARMACEUTICAL AGENT;

CANCER SCINTISCANNING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HUMAN; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); ONCOLOGY; REVIEW; SYSTEMATIC REVIEW; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; EVIDENCE BASED MEDICINE; MULTIMODAL IMAGING; NEOPLASMS; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; SCINTISCANNING;

EVIDENCE-BASED MEDICINE; FLUORODEOXYGLUCOSE F18; HUMANS; MEDICAL ONCOLOGY; MULTIMODAL IMAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84906935978     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-014-1168-8     Document Type: Review

References (33)

1. Tagliabue L, Del Sole A. Appropriate use of positron emission tomography with [(18)F]fluorodeoxyglucose for staging of oncology patients. Eur J Intern Med. 2014;25:6-11.
2. Treglia G, Sadeghi R. Meta-analyses and systematic reviews on PET and PET/CT in oncology: the state of the art. Clin Transl Imaging. 2013;1:73-5.
3. Umbehr MH, Müntener M, Hany T, Sulser T, Bachmann LM. The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol. 2013;64:106-17.
4. Evangelista L, Guttilla A, Zattoni F, Muzzio PC, Zattoni F. Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis. Eur Urol. 2013;63:1040-8.
5. Evangelista L, Zattoni F, Guttilla A, Saladini G, Zattoni F, Colletti PM, et al. Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis. Clin Nucl Med. 2013;38:305-14.
6. Evangelista L, Cervino AR, Burei M, Gregianin M, Saladini G, Marzola MC, et al. Comparative studies of radiolabeled choline positron emission tomography, histology of primary tumor and other imaging modalities in prostate cancer: a systematic review and meta-analysis. Clin Transl Imaging. 2013;1:99-109.
7. von Eyben FE, Kairemo K. Meta-analysis of 11C-choline and 18F-choline PET/CT for management of patients with prostate cancer. Nucl Med Commun. 2014;35:221-30.
8. Treglia G, Ceriani L, Sadeghi R, Giovacchini G, Giovanella L. Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET/CT in restaging prostate cancer patients: a meta-analysis. Clin Chem Lab Med. 2013. doi:10.1515/cclm-2013-0675.
9. Mohsen B, Giorgio T, Rasoul ZS, Werner L, Ali GR, Reza DK, et al. Application of (11) C-acetate positron-emission tomography (PET) imaging in prostate cancer: systematic review and meta-analysis of the literature. BJU Int. 2013;112:1062-72.
10. Tateishi U, Morita S, Taguri M, Shizukuishi K, Minamimoto R, Kawaguchi M, et al. A meta-analysis of (18)F-Fluoride positron emission tomography for assessment of metastatic bone tumor. Ann Nucl Med. 2010;24:523-31.
11. Tateishi U, Morita S, Inoue T. Diagnostic accuracy of 18F-fluoride PET and PET/CT in patients with bone metastases: a systematic review and meta-analysis update. Clin Transl Imaging. 2013;1:123-34.
12. Dunet V, Rossier C, Buck A, Stupp R, Prior JO. Performance of 18F-fluoroethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and Metaanalysis. J Nucl Med. 2012;53:207-14.
13. Dunet V, Prior JO. Diagnostic accuracy of F-18-fluoroethyltyrosine PET and PET/CT in patients with brain tumor. Clin Transl Imaging. 2013;1:135-44.
14. Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR. 2013;34:944-50.
15. Zhao C, Zhang Y, Wang J. A meta-analysis on the diagnostic performance of 18F-FDG and 11C-methionine PET for differentiating brain tumors. AJNR. 2013. doi:10.3174/ajnr.A3718.
16. 11C-methionine positron emission tomography and dynamic susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun. 2013;34:758-66.
17. 11C-methionine in patients with suspected parathyroid adenoma: a meta-analysis. Endocrine. 2013;43:78-83.
18. Treglia G, Castaldi P, Rindi G, Giordano A, Rufini V. Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine. 2012;42:80-7.
19. Geijer H, Breimer LH. Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2013;40:1770-80.
20. Yang J, Kan Y, Ge BH, Yuan L, Li C, Zhao W. Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis. Acta Radiol. 2013. doi:10.1177/0284185113496679.
21. Treglia G, Cocciolillo F, de Waure C, Di Nardo F, Gualano MR, Castaldi P, et al. Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis. Eur J Nucl Med Mol Imaging. 2012;39:1144-53.
22. Treglia G, Cocciolillo F, Di Nardo F, Poscia A, de Waure C, Giordano A, et al. Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 dihydroxyphenylalanine positron emission tomography: a meta-analysis. Acad Radiol. 2012;19:1290-9.
23. Rufini V, Treglia G, Montravers F, Giordano A. Diagnostic accuracy of [18F]DOPA PET and PET/CT in patients with neuroendocrine tumors: a meta-analysis. Clin Transl Imaging. 2013;1:111-22.
24. Treglia G, Mirk P, Giordano A, Rufini V. Diagnostic performance of fluorine-18-dihydroxyphenylalanine positron emission tomography in diagnosing and localizing the focal form of congenital hyperinsulinism: a meta-analysis. Pediatr Radiol. 2012;42:1372-9.
25. Blomberg BA, Moghbel MC, Saboury B, Stanley CA, Alavi A. The value of radiologic interventions and (18)F-DOPA PET in diagnosing and localizing focal congenital hyperinsulinism: systematic review and meta-analysis. Mol Imaging Biol. 2013;15:97-105.
26. Yang J, Hao R, Zhu X. Diagnostic role of 18F-dihydroxyphenylalanine positron emission tomography in patients with congenital hyperinsulinism: a meta-analysis. Nucl Med Commun. 2013;34:347-53.
27. Treglia G, Giovannini E, Di Franco D, Calcagni ML, Rufini V, Picchio M, et al. The role of positron emission tomography using carbon-11 and fluorine-18 choline in tumors other than prostate cancer: a systematic review. Ann Nucl Med. 2012;26:451-61.
28. Mattoli MV, Treglia G, Trevisi G, Muoio B, Cason E. Usefulness of 11C-methionine positron emission tomography in differential diagnosis between recurrent tumours and radiation necrosis in patients with glioma: an overview. Open Neurosurg J. 2012;5:8-11.
29. Volterrani D, Orsini F, Chiacchio S, Bodei L. Multiagent targeting of neuroendocrine neoplasms. Clin Transl Imaging. 2013;1:407-21.
30. Larson SM, Mariani G, Strauss HW. Tumor biology as a basis for molecular targeting in cancer. Clin Transl Imaging. 2013;1:397-406.
31. Picchio M. PET/MRI. Clin Transl Imaging. 2013;1:3-4.
32. Ratib O. PET/MRI: a new era in multimodality molecular imaging. Clin Transl Imaging. 2013;1:5-10.
33. Pace L, Nicolai E, Aiello M, Catalano OA, Salvatore M. Whole-body PET/MRI in oncology: current status and clinical applications. Clin Transl Imaging. 2013;1:31-44.